Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px
Organisation › Details

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". *

 

Period Start 1992-01-01 established
  Group MorphoSys (Group)
  Predecessor MorphoSys GmbH
Product Industry biopharmaceutical
Persons Person Moroney, Simon E. (MorphoSys 1992– CEO + Founder)
  Person 2 Holstein, Jens (MorphoSys 201105– CFO before Regional CFO Fresenius Kabi + Managing Director Fresenius Kabi Deutschland)
     
Region Region Martinsried
  Country Germany
  Street 48 Lena-Christ-Str.
  City 82152 Martinsried
  Tel +49-89-89927-0
  Fax +49-89-89927-222
     
Basic data Employees D: 101 to 500 (2016-12-31)
  Currency EUR
  Annual sales 49,743,515 (revenues, consolidated (2016) 2016-12-31)
  Profit -60,382,776 (2016-12-31)
  Cash 73,928,661 (2016-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2017-12-04

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px